JOINT INFORMATIONAL HEARING
ASSEMBLY HEALTH AND JUDICIARY COMMITTEES
Tuesday, March 12, 2002
1:30 p.m. to 4:00 p.m.
State Capitol, Room 4202

BACKGROUND

AGENDA – Part II

Implementation of Independent Medical Review

Independent Medical Review (IMR) is a way for patients to appeal to physicians and other health care professionals outside the patient's health plan to make an independent decision about their health care. IMR programs provide an independent review of a health plan’s decision to deny, modify, or delay care. Devised initially by insurance regulators in a handful of states, by Medicare, and by some managed care plans to help resolve disputes over difficult cases, IMR programs are used by most states and in the private sector. IMR is meant to address concerns about managed care incentives that might lead to the inappropriate denial of care, and to help restore public confidence in managed care. IMR, also known as external review, is widely cited as a fair, impartial, and usually expeditious and cost effective way to resolve disputes, and is used by more than 35 states.

Enacted through the Friedman-Knowles Experimental Treatment Act of 1996, California's initial IMR law required health plans to establish a reasonable external, independent review process to examine health plan coverage decisions regarding experimental or investigational therapies for individual enrollees who were terminally ill and met other specified criteria.

In 1999, the California Legislature passed and Governor Davis signed into law a package of HMO reforms. Included in those reforms was AB 55 (Migden and Thomson), Chapter 533,
Statutes of 1999, which established, effective January 1, 2001, the Independent Medical Review System for health plan denials based on medical necessity, and SB 189 (Schiff), Chapter 542, Statutes of 1999. SB 189 broadened eligibility for the Friedman-Knowles Experimental Treatment Act from terminally ill patients to patients with life-threatening or seriously debilitating conditions and required the health plans' regulator to contract with the independent review organization (IRO), instead of the plan contracting with an IRO directly.iv

After an overview of IMR by Daniel Zingale, Director of the Department of Managed Health Care (DMHC), the members of the Assembly Health and Judiciary Committees will hear testimony from patients, consumer advocates, researchers, physicians and health plans on how IMR is working in California. The following discussion questions were sent to panel participants in advance of the hearing.

Discussion Questions

1) What is Independent Medical Review (IMR) and why is IMR important?

2) What types of cases go to IMR? What is the criteria used to determine eligibility for IMR?

3) What appear to be the principal complaints about IMR being expressed by patient users?

4) How do California's results compare to the rest of the nation? Can any conclusions be drawn from the data to date?

5) If a patient pays and obtains a service after the plan denies it as not medically necessary, is the denial eligible for IMR? If not, should it be?

6) In a delegated medical group, are patients being made aware of their right to IMR if the patient is denied care by the medical group? What is being done to monitor and enforce notice requirements and the right to IMR when the service denial is from a delegated medical group?

7) If an independent review panel requires a health plan to cover a particular treatment or therapy, is the decision binding on the plan for other enrollees with the same condition or is it limited to that particular enrollee?

8) What percentage of the applications for IMR actually went through and completed the IMR process? What were the reasons for the other applications not being eligible for IMR or not completing the IMR process?

9) What oversight exists regarding the IMR contractor's (Center for Health Dispute Resolution [CHDR]) performance? How will DMHC and the Legislature know if CHDR is doing a good job?
10) How does CHDR determine the composition of its expert panels? Are differences in subspecialty, training, knowledge and biases taken into consideration?

11) How do patients learn about the IMR process? Is there a need for additional enrollee education?

12) Is DMHC starting to see trends in the types of cases that go to IMR and health plan denials of care?

13) Should there be greater public disclosure of the clinical issues and health plan involved in each IMR case?

Who is Eligible for IMR?

Individuals eligible for IMR include those enrolled in "full service" health care service plans (generally HMOs such as Kaiser, Foundation Health Plan and HealthNet) and managed behavioral health plans (such as PacifiCare Behavioral Health Plan of California, Inc.) regulated by DMHC, health insurers regulated by the Department of Insurance (such as Hartford Life and Accident Insurance Company and CalFarm), and Medi-Cal managed care plans providing health care coverage to Medi-Cal beneficiaries (such as Health Plan of San Mateo, LA Care Health Plan).

A health plan enrollee can apply for an IMR when:

- the enrollee's provider has recommended a health care service as medically necessary;
- the enrollee has received urgent care or emergency services that a provider determined was medically necessary; or,
- the enrollee, in the absence of a provider recommendation or the receipt of urgent care or emergency services by a provider, has been seen by an in-plan provider for the diagnosis or treatment of the medical condition for which the enrollee seeks independent review.

To be eligible for IMR, a health plan enrollee must meet one of the following conditions:

1) Had medical services or treatment denied, delayed, or modified by the plan or one of its contracting medical providers based in whole or in part on a decision that the care is not medically necessary. In most cases, the patient must first complete the health plan's grievance process or participate in the plan's grievance process for at least 30 days;
2) Had medical services or treatment denied for a life-threatening or seriously debilitating condition because it was determined to be "experimental or investigational;" or,
3) Had received emergency or urgent medical services or treatment, but the health plan denied reimbursement on the grounds the service was not medically necessary.

Additionally, the patient must have received a decision from his or her health plan or its contracting medical provider stating:

1) Denial of experimental/investigational treatment;

2) Denial, delay, or modification of services based upon the finding that the care is not medically necessary; or,

3) Denial of reimbursement for emergency/urgent care.

Medical Necessity vs. a Coverage Decision

To be eligible for IMR, a patient's case must involve a "disputed health care service." A disputed health care service means any health care service eligible for coverage and payment under a health plan contract that has been denied, modified, or delayed by a decision of the plan, or by one of its contracting providers, in whole or in part due to a finding that the service is not medically necessary.

Health plan coverage decisions are not subject to IMR. A "coverage decision" is defined as the approval or denial of health care services by a plan, or by one of its contracting entities, substantially based on a finding that the provision of a particular service is included or excluded as a covered benefit under the terms and conditions of the health plan contract. If a plan, or one of its contracting providers, issues a decision denying, modifying, or delaying health care services, based in whole or in part on a finding that the proposed health care services are not a covered benefit under the contract that applies to the enrollee, the statement of decision is required to clearly specify the provision in the contract that excludes that coverage.

The health plan's regulator is the final arbiter when there is a question as to whether an enrollee grievance is a disputed health care service or a coverage decision.

DMHC contracts with Maximus/Center for Health Dispute Resolution (CHDR) to administer the IMR program. CHDR has handled external reviews for the Medicare program since 1988 and does business for 23 other states.

Criteria Used by the Medical Reviewers

Upon receipt of information and documents related to a case, the medical professional reviewer or reviewers selected to conduct the review by the independent medical review organization (CHDR) is required to promptly review all pertinent medical records of the enrollee, provider reports, as well as any other information submitted to the organization.
Following its review, the reviewer or reviewers determine whether the disputed health care service was medically necessary based on the specific medical needs of the enrollee and any of the following:

- Peer-reviewed scientific and medical evidence regarding the effectiveness of the disputed service;
- Nationally recognized professional standards;
- Expert opinion;
- Generally accepted standards of medical practice; or,
- Treatments that are likely to provide a benefit to a patient for conditions for which other treatments are not clinically efficacious.

The organization is required to complete its review and make its determination in writing, and in layperson's terms to the maximum extent practicable, within 30 days of the receipt of the application for review and supporting documentation, or within less time as prescribed by the plan's regulator. The medical professionals' analyses and determinations are required to state whether the disputed health care service is medically necessary. Following a decision, the director is required to immediately adopt the determination of the independent medical review organization, and to promptly issue a written decision to the parties that is binding on the plan.

After removing the names of the parties, including, but not limited to, the enrollee, all medical providers, the plan, and any of the insurer's employees or contractors, decisions adopting a determination of an independent medical review organization are made available by the regulator to the public upon request. DMHC provides on its web site a database of IMR decisions that is searchable by diagnosis category or treatment category that contains a brief summary of the case. The first example falls under the diagnosis category of "prevention" in which the health plan decision was upheld, and the second case falls under the diagnosis category "mental disorder" and involves a health plan being overturned.

**Case Details**

<table>
<thead>
<tr>
<th>Reference ID #</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>MN01-000132</td>
<td>Medical Necessity</td>
</tr>
</tbody>
</table>

| Prevention                      | Diagnostic Imaging / Screening |

Upheld Decision of Health Plan
A 60-year-old female requested a colonoscopy as a cancer screening. The health plan denied the request indicating the requested procedure is not medically necessary, and the health plan recommended a sigmoidoscopy and a fecal occult blood test. The Review Organization's Physician Consultant examined the medical records submitted and determined there is no indication that this patient is at increased risk for colon cancer. The Health Plan’s denial should be upheld.

**Case Details**

<table>
<thead>
<tr>
<th>Reference ID #</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>MN01-000300</td>
<td>Medical Necessity</td>
</tr>
</tbody>
</table>

Mental Disorder          Mental Health

Overturned Decision of Health Plan

*Case Details*
A 54-year-old female requested weekly cognitive therapy by an out-of-network provider for treatment of behavioral problems. The Health Plan denied the request indicating the service can be provided in-plan consistent with weekly group therapy, monthly visits with a LCSW and consults with a psychiatrist every two months for medication review. The Health Plan has a brief treatment model using cognitive and behavioral techniques, through group therapy, and when necessary individually. Individual treatment occurs on a frequency of two to four weeks between sessions. The Review Organization's Physician Consultant examined the medical records submitted and determined the enrollee has multiple problems; depression, PTSD, anxiety as well as serious psychodynamic cognitive and behavioral issues. The mode of therapy, i.e., cognitive, behavioral or psychodynamic or a combination in a group setting or individual setting can vary depending upon assessment of the enrollee at a given point in time. The enrollee is described as a very high suicidal risk, which would exacerbate if continued treatment with the out-of-network provider was disrupted. Therefore, the health plan’s denial should be overturned.

Upon receiving the decision adopted by the director that a disputed health care service is medically necessary, the health plan is required to promptly implement the decision. In the case of reimbursement for services already rendered, the plan is required to reimburse the provider or enrollee, whichever applies, within five working days.

The health plan's regulator is required to establish a reasonable, per-case reimbursement schedule to pay the costs of IMR organization reviews, which may vary depending on the type of medical condition under review and on other relevant factors. The costs of the independent medical review system for enrollees are required to be borne by health plans pursuant to an assessment fee system established by their regulator.

Disclosure to Health Plan Enrollees
To notify patients of their right to IMR, every health plan is required to prominently display information concerning the right of an enrollee to request an independent medical review on the following documents:

- every health plan member handbook or relevant informational brochure;
- in every health plan contract;
- on enrollee evidence of coverage forms;
- on copies of health plan procedures for resolving grievances;
- on letters of denials issued by either the health plan or its contracting organization;
- on grievance forms; and,
- on all written responses to grievances.

Report to the Legislature

The Director of DMHC is required to submit to the Legislature by March 1, 2002, a report on the initial implementation of IMR which includes a description of assessments imposed on plans to implement IMR, increased staffing and other resources attributable to these new responsibilities, and any redirection of existing staff and resources to carry out these responsibilities. As of March 6, 2002, that report has not yet been furnished.

Clinical Advisory Panel

AB 78 (Gallegos), Chapter 525, Statues of 1999, created DMHC and established in DMHC a Clinical Advisory Panel (CAP). The CAP consists of five members appointed by the director, three of whom are professors of medicine from California's public and private medical schools and two of whom are practicing physicians. CAP is required to meet quarterly, and its purpose is to:

- Provide expert assistance to the director by ensuring that the external independent review system is meeting the quality standards necessary to protect the public's interest.

- Assist the director with other clinical issues as needed, such as recommending approaches to globally reduce clinical errors, improving patient safety, increasing the practice of evidence-based medicine, and catalyzing clinical studies when a clear need for additional clinical evidence becomes evident.

- Review the decisions made in external review to ensure that the decisions are consistent with best practices, and to make recommendations for improvements where necessary.

Litigation Involving IMR

The U.S. Supreme Court has under review *Rush Prudential HMO Inc. v. Moran* after hearing oral arguments in January 2002. The case raises the issue as to whether the independent
physician review provision of an Illinois law, similar to California law and laws adopted in 36
states and the District of Columbia, is preempted by the Employee Retirement Income Security
Act of 1974 (ERISA). The impact of the court's decision in this case will be the future viability
and enforcement of current state laws, which are designed to help patients deal with denials of
care by HMOs or their contracting entities. The court's decision will ultimately determine any
state's ability to regulate managed care, and material modifications of managed care agreements
may be necessary after the decision is rendered.

The case involves an Illinois woman, Debra Moran, who decided to pay for a $94,841.27
operation herself after her HMO, Rush Prudential, refused coverage. Moran sued the insurer and
won a state court order that required Rush Prudential to submit to independent physician review
as mandated by the Illinois HMO Act. The insurer complied but denied, as medically
unnecessary, Moran's request for full coverage of the surgery by the outside surgeon.

In September, 2001, a Blue Shield member's physician submitted a request to Blue Shield
requesting that the member's prescription for the weight loss drug Xenical be covered by Blue
Shield under one of their outpatient prescription drug benefit plans. Outpatient prescription
weight loss drugs are specifically excluded from the member's plan. Blue Shield denied the
member's physician's request for coverage for Xenical, informing the member that outpatient
prescription drugs for weight loss are specifically excluded.

The member then appealed Blue Shield's denial of coverage, and that appeal was denied on the
ground that weight loss medications are not a covered benefit under the member's outpatient
prescription drug benefit package. The member applied for an IMR of Blue Shield's decision not
to provide coverage for the member's Xenical prescription, CHDR performed an IMR for the
member and determined that the medication Xenical was medically necessary for the treatment of
the member's medical condition. CHDR accordingly decided that Blue Shield's denial of
coverage for Xenical should be overturned. DMHC adopted this decision on October 26, 2001,
finding that because CHDR had determined Xenical was "medically necessary" for the treatment
of the member's medical condition, Blue Shield was required to provide coverage for the
medication. Blue Shield refused to comply with DMHC's decision but continued to provide the
drug pending the outcome of the case.

On November 16, 2001, DMHC filed an accusation against Blue Shield seeking to impose a
$100,000 administrative penalty against Blue Shield and an additional penalty of $5,000 per day
from November 2, 2001, until Blue Shield provides coverage for the member's outpatient
prescription of Xenical. In December 2001, Blue Shield sought a declaratory judgment that the
denial of coverage for outpatient prescription drug benefits based on an exclusion of coverage is
not subject to an IMR and that, in such cases, the Department may not approve members'
requests for an IMR or adopt, rely upon, or consider the conclusions of any such IMR.
Additionally, Blue Shield sought a permanent injunction to enjoin (prohibit) DMHC from
authorizing an IMR for Blue Shield outpatient prescription drug benefit coverage decisions,
when those coverage decisions are not based, in whole or in part, on a finding that an outpatient
prescription drug is not medically necessary, and a permanent injunction to enjoin DMHC, from
adopter, relying upon, or considering the results of any IMR of Blue Shield outpatient prescription drug benefit coverage decision under IMR, when those coverage decisions are not based, in whole or in part, on a finding that the outpatient prescription drug is not medically necessary, absent an express statutory mandate.

On January 15, 2002, a Sacramento Superior Court judge issued a preliminary injunction enjoining DMHC from authorizing an IMR for Blue Shield's outpatient prescription drug benefit coverage decisions when those decisions are not based on a finding that the outpatient prescription drug is medically necessary. Additionally, the judge enjoined DMHC from adopting the results of any IMR review of Blue Shield outpatient prescription drug benefit coverage when those coverage decisions are based on a finding that the outpatient prescription drug is not medically necessary, absent an express statutory mandate. Blue Shield has continued to provide the drug to the enrollee whose case went to IMR and to enrollees who requested the drug prior to January 15th but has denied the drug since the judge's injunction.
## Department of Managed Health Care IMR Data

<table>
<thead>
<tr>
<th>Calendar Year 2001</th>
<th>Beginning Balance</th>
<th>IMRs Received</th>
<th>IMRs Not Eligible</th>
<th>IMRs Resolved IMRO</th>
<th>Other</th>
<th>Ending Balance</th>
</tr>
</thead>
<tbody>
<tr>
<td>January</td>
<td>0</td>
<td>30</td>
<td>17</td>
<td>1</td>
<td>0</td>
<td>12</td>
</tr>
<tr>
<td>February</td>
<td>12</td>
<td>82</td>
<td>34</td>
<td>9</td>
<td>2</td>
<td>49</td>
</tr>
<tr>
<td>March</td>
<td>49</td>
<td>134</td>
<td>88</td>
<td>36</td>
<td>0</td>
<td>59</td>
</tr>
<tr>
<td>April</td>
<td>59</td>
<td>119</td>
<td>61</td>
<td>54</td>
<td>5</td>
<td>58</td>
</tr>
<tr>
<td>May</td>
<td>58</td>
<td>173</td>
<td>58</td>
<td>59</td>
<td>10</td>
<td>104</td>
</tr>
<tr>
<td>June</td>
<td>104</td>
<td>200</td>
<td>106</td>
<td>49</td>
<td>24</td>
<td>125</td>
</tr>
<tr>
<td>July</td>
<td>125</td>
<td>146</td>
<td>109</td>
<td>67</td>
<td>24</td>
<td>71</td>
</tr>
<tr>
<td>August</td>
<td>71</td>
<td>208</td>
<td>112</td>
<td>47</td>
<td>15</td>
<td>105</td>
</tr>
<tr>
<td>September</td>
<td>105</td>
<td>171</td>
<td>105</td>
<td>53</td>
<td>5</td>
<td>113</td>
</tr>
<tr>
<td>October</td>
<td>113</td>
<td>195</td>
<td>145</td>
<td>62</td>
<td>1</td>
<td>100</td>
</tr>
<tr>
<td>November</td>
<td>100</td>
<td>153</td>
<td>86</td>
<td>69</td>
<td>8</td>
<td>90</td>
</tr>
<tr>
<td>December</td>
<td>90</td>
<td>117</td>
<td>63</td>
<td>59</td>
<td>12</td>
<td>73</td>
</tr>
<tr>
<td><strong>Year-to-Date Totals</strong></td>
<td><strong>1,728</strong></td>
<td><strong>984</strong></td>
<td><strong>671</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

In 2001, of the 1,728 IMR requests received, 984 or 57% were not eligible for IMR. 671 of the 1,728 IMR requests were resolved (39%), with 84% of the cases resolved being resolved through IMR.
## Department of Managed Health Care IMR Data

<table>
<thead>
<tr>
<th>Month</th>
<th>Balance</th>
<th>Sent E/I</th>
<th>Upheld E/I</th>
<th>Overturned E/I</th>
<th>Withdrawn E/I</th>
<th>Pending E/I</th>
<th>Sent MN</th>
<th>Upheld MN</th>
<th>Overturned MN</th>
<th>Withdrawn MN</th>
<th>Pending MN</th>
</tr>
</thead>
<tbody>
<tr>
<td>January</td>
<td>0</td>
<td>4 E/I</td>
<td>1 E/I</td>
<td>0 E/I</td>
<td>0 E/I</td>
<td>0 E/I</td>
<td>1 MN</td>
<td>0 MN</td>
<td>0 E/I</td>
<td>0 E/I</td>
<td>4 E/I</td>
</tr>
<tr>
<td>February</td>
<td>4</td>
<td>4 E/I</td>
<td>3 E/I</td>
<td>0 E/I</td>
<td>2 E/I</td>
<td>2 E/I</td>
<td>18 MN</td>
<td>3 MN</td>
<td>10 E/I</td>
<td>0 E/I</td>
<td>15 MN</td>
</tr>
<tr>
<td>March</td>
<td>15</td>
<td>21 E/I</td>
<td>9 E/I</td>
<td>3 E/I</td>
<td>10 E/I</td>
<td>0 E/I</td>
<td>45 MN</td>
<td>37 E/I</td>
<td>37 MN</td>
<td>45 E/I</td>
<td>0 MN</td>
</tr>
<tr>
<td>April</td>
<td>45</td>
<td>18 E/I</td>
<td>17 E/I</td>
<td>2 E/I</td>
<td>12 E/I</td>
<td>5 E/I</td>
<td>33 MN</td>
<td>33 E/I</td>
<td>17 MN</td>
<td>33 E/I</td>
<td>37 E/I</td>
</tr>
<tr>
<td>June</td>
<td>27</td>
<td>17 E/I</td>
<td>5 E/I</td>
<td>3 E/I</td>
<td>15 E/I</td>
<td>7 E/I</td>
<td>52 MN</td>
<td>52 E/I</td>
<td>41 MN</td>
<td>52 E/I</td>
<td>41 MN</td>
</tr>
<tr>
<td>September</td>
<td>39</td>
<td>14 E/I</td>
<td>11 E/I</td>
<td>2 E/I</td>
<td>14 E/I</td>
<td>4 E/I</td>
<td>41 MN</td>
<td>41 E/I</td>
<td>41 E/I</td>
<td>41 E/I</td>
<td>41 MN</td>
</tr>
<tr>
<td>November</td>
<td>48</td>
<td>14 E/I</td>
<td>14 E/I</td>
<td>3 E/I</td>
<td>28 E/I</td>
<td>8 E/I</td>
<td>45 MN</td>
<td>45 E/I</td>
<td>45 E/I</td>
<td>45 E/I</td>
<td>45 MN</td>
</tr>
<tr>
<td>December</td>
<td>45</td>
<td>5 E/I</td>
<td>11 E/I</td>
<td>0 E/I</td>
<td>22 E/I</td>
<td>5 E/I</td>
<td>37 MN</td>
<td>37 E/I</td>
<td>37 E/I</td>
<td>37 E/I</td>
<td>37 MN</td>
</tr>
</tbody>
</table>

**E/I** – Experimental/Investigational  
**MN** – Medical Necessity

In 2001, of the 650 IMR requests sent to IMR, the health plan was upheld in 354 cases (54%) and 211 (32%) with the health plan being overturned, with the remainder being withdrawn or still pending. Of the 650 IMR requests, 153 were experimental/investigational requests for IMR. For the 153 cases sent to IMR involving experimental/investigational treatment, the plan was upheld in 119 cases (78%) and overturned in 27 (18%), with the remainder being withdrawn or still pending. Of the 650 IMR requests, 497 were medical necessity requests for IMR. For the 497 cases sent to IMR involving medical necessity, the plan was upheld in 235 cases (47%) and overturned in 184 (37%), with the remainder being withdrawn or still pending.


iii AB 1663 (Friedman and Knowles), Chapter 979, Statutes of 1996.

iv SB 189 (Schiff and Migden), Chapter 542, Statutes of 1999.

v Health and Safety Code Section 1374.36.

vi Health and Safety Code Section 1347.1.

vii Complaint for Declaratory and Injunctive Relief and Notice of Related Case Filed Concurrently Herewith), Quinn Emanuel Urquhart Oliver & Hedges, LLP, Steven G. Madison, J.D. Horton, Brian D. Henri, Attorneys for Plaintiff California Physicians’ Service dba Blue Shield of California.

viii Order Re Plaintiff’s Motion for A Preliminary Injunction by Joe S. Gray, Judge of the Superior Court, Superior Court of the State of California For the County of Sacramento, January 15, 2002.